Novo NVO announced new real-world data from the COMPETE SWITCH Cardiovascular (CV) study comparing treatment strategies in adults with type II diabetes (T2D) who were already receiving a 1-mg dose of Ozempic (semaglutide) injection. The analysis found that patients who increased their Ozempic dose had a lower observed risk of major adverse cardiovascular events (MACE) than those who switched to Lilly's LLY Mounjaro (tirzepatide). Ozempic and Mounjaro are competing therapies in the U.S. diabetes market. Ozempic is a once-weekly GLP-1 receptor agonist developed by Novo.
Mostramos la idea principal publicamente. Crea una cuenta gratis para seguir leyendo el articulo completo, guardarlo, comentarlo y conectarlo con contexto de mercados y OSINT.